• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cardiovascular societies outline return to medical, surgical procedures

Cardiovascular societies outline return to medical, surgical procedures

May 5, 2020 By Nancy Crotti

A group of North American cardiovascular societies released guidance today on the resumption of heart-related procedures in light of the COVID-19 pandemic.

The guidance, scheduled to be published in a future issue of the Journal of the American College of Cardiology, takes into account regional differences in the intensity of the outbreak.

Most invasive cardiovascular procedures and diagnostic tests have been deferred within North America, resulting in waiting lists for patients at increased risk of adverse outcomes, the groups said. Reduced access to diagnostic testing will lead to a high burden of undiagnosed cardiovascular disease that will further delay time to treatment, they added.

“Although there will be a myriad of competing demands from multiple disciplines, this risk warrants the prioritization of cardiovascular patients as healthcare systems return to normal capacity,” the societies concluded.

Here are some of their recommendations:

  • Hospital-based cardiovascular teams must exchange establish active, up-to-date information on both the local status of the pandemic and the growing morbidity and mortality on cardiovascular procedure waiting lists.
  • There should be a sustained reduction in the rate of new COVID-19 admissions and deaths as determined by local public health officials before procedures can resume. If COVID-19 admissions and deaths start to increase, most elective invasive procedures and tests should cease immediately.
  • Routine screening of patients and healthcare workers for COVID-19.
  • Careful use and monitoring of personal protective equipment (PPE) inventory to minimize the risk of shortages.
  • An expectation of using the highest-level of PPE during emergency cardiovascular cases or for aerosol-generating medical procedures.
  • Physical distancing efforts, including virtual pre-procedural clinics, virtual consenting for procedures and diagnostic tests, and minimizing the number of healthcare workers in physical contact with any given patient.
  • Other strategies, such as greater use of minimally invasive procedures, if effective; shorter length of stay; less invasive tests; and alternative imaging.

“This consensus report provides harmonized guidance from North American cardiovascular societies,” the groups said in the article. “It provides an ethical framework with appropriate safeguards for the gradual reintroduction of invasive cardiovascular procedures and diagnostics tests after the initial peak of the COVID-19 pandemic. A collaborative approach will be essential to mitigate the ongoing morbidity and mortality associated with untreated cardiovascular disease.”

 

 

Filed Under: Cardiovascular, Featured, Hospital Care, Surgical Tagged With: coronavirus, COVID-19, Journal of the American College of Cardiology

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy